Clinical phenotypes in sarcoidosis

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 5, 2014, Pages 496-502

  Pereira, Carlos A C ^a   Dornfeld, Marina C ^a   Baughman, Robert ^b   Judson, Marc A ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

granuloma; interstitial lung diseases; phenotyping; sarcoidosis

Indexed keywords

GENOTYPE; HUMAN; PATHOLOGY; PHENOTYPE; SARCOIDOSIS; SEVERITY OF ILLNESS INDEX;

GENOTYPE; HUMANS; PHENOTYPE; SARCOIDOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84906055118     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000077     Document Type: Review

References (75)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February. Am J Respir Crit Care Med 1999; 160: 736-755.
2. Grunewald J. Review: role of genetics in susceptibility and outcome of sarcoidosis. Semin Respir Crit Care Med 2010; 31:380-389.
3. Judson M.A. The etiologic agent of sarcoidosis: what if there isn't one? Chest 2003; 124:6-8.
4. Sato H, Woodhead FA, Ahmad T, et al. Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Hum Mol Genet 2010; 19:4100-4111.
5. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18:716-725.
6. Haldar P, Berair R. Endotypes and asthma. In: Bernstein JS, Levy M, editors. Clinical asthma. Theory and practice. Boca Raton: CRC Press; 2014. pp. 39-43.
7. Grunewald J, Eklund A. Sex-specific manifestations of Lö fgren's syndrome. Am J Respir Crit Care Med 2007; 175:40-44.
8. Grunewald J. HLA associations and Löfgren's syndrome. Expert Rev Clin Immunol 2012; 8:55-62.
9. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182:598-604.
10. Agust́i A. Phenotypes and disease characterization in chronic obstructive pulmonary disease. Toward the extinction of phenotypes? Ann Am Thorac Soc 2013; 10 (Suppl):S125-S130.
11. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012; 42:650-658.
12. Wasfi YS, Rose CS, Murphy JR, et al. A new tool to assess sarcoidosis severity. Chest 2006; 129:1234-1245.
13. Prasse A, Katic C, Germann M, et al. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med 2008; 177:330-336.
14. Baughman RP, Nagai S, Balter M, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28:56-64.
15. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-224.
16. Alves Rde S, Vianna Fde A, Pereira CA. Clinicalphenotypes ofsevereasthma. J Bras Pneumol 2008; 34:646-653.
17. Lin TY, Poon AH, Hamid Q. Asthma phenotypes and endotypes. Curr Opin Pulm Med 2013; 19:18-23.
18. Rodrigues SC, Rocha NA, Lima MS, et al. Factor analysis of sarcoidosis phenotypes at two referral centers in Brazil. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28:34-43.
19. Agusti A, MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax 2013; 68:687-690.
20. Judson M.A. A proposed solution to the clinical assessment of sarcoidosis: the sarcoidosis three-dimensional assessment instrument (STAI). Med Hypotheses 2007; 68:1080-1087.
21. Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:19-27.
22. Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132:1949-1953.
23. Hostettler KE, Bratu VA, Fischmann A, et al. Whole-body magnetic resonance imaging in extrathoracic sarcoidosis. Eur Respir J 2014; 43:1812-1815.
24. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 52: 525-533.
25. Baughman RP, Lower EE. Six-minute walk test in managing and monitoring sarcoidosis patients. Curr Opin Pulm Med 2007; 13:439-444.
26. Marcellis RG, Lenssen AF, de Vries J, Drent M. Reduced muscle strength, exercise intolerance and disabling symptoms in sarcoidosis. Curr Opin Pulm Med 2013; 19:524-530.
27. Baydur A, Alsalek M, Louie SG, Sharma OP. Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis. Chest 2001; 120: 102-108.
28. Judson M.A. Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:204-211.
29. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111: 623-631.
30. Pietinalho A, Ohmichi M, Lofroos AB, et al. The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17:158-166.
31. Baughman RP. Presenting characteristics as predictors of duration of treatment in sarcoidosis. Q J Med 2006; 99:307-315.
32. Lynch JP 3rd, Ma YL, Koss MN, White ES. Pulmonary sarcoidosis. Semin Respir Crit Care Med 2007; 28:53-74.
33. Mana J, Salazar A, Pujol R, Manresa F. Are the pulmonary function tests and the markers of activity helpful to establish the prognosis of sarcoidosis? Respiration 1996; 63:298-303.
34. Laohaburanakit P, Chan A. Obstructive sarcoidosis. Clin Rev Allergy Immunol 2003; 25:115-129.
35. Naccache JM, Lavolé A, Nunes H, et al. High-resolution computed tomo-graphic imaging of airways in sarcoidosis patients with airflow obstruction. J Comput Assist Tomogr 2008; 32:905-912.
36. Hansell DM, Milne DG, Wilsher ML, Wells AU. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. Radiology 1998; 209:697-704.
37. Nunes H, Humbert M, Capron F, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61:68-74.
38. Baughman RP, Engel PJ, Meyer CA, et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:108-116.
39. Medinger AE, Khouri S, Rohatgi PK. Sarcoidosis: the value of exercise testing. Chest 2001; 120:93-101.
40. Barros WG, Neder JA, Pereira CA, Nery LE. Clinical, radiographic and functional predictors of pulmonary gas exchange impairment at moderate exercise in patients with sarcoidosis. Respiration 2004; 71:367-373.
41. Marcellis RG, Lenssen AF, De Vries GJ, et al. Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients? Lung 2013; 191:247-256.
42. Wells A, Parfrey H, Ward S, Cramer D. Staging and monitoring pulmonary sarcoidosis: pulmonary function tests and other variables. In: Mitchell D, Wells A, Spiro S, Moller D, editors. Sarcoidosis. London: Hodder Arnold; 2012. pp. 102-112.
43. Viskum K, Vestbo J. Vital prognosis in intrathoracic sarcoidosis with special reference to pulmonary function and radiological stage. Eur Respir J 1993; 6:349-353.
44. Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014; 2:123-130.
45. Baughman RP, Drent M, Culver DA, et al. Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29:90-98.
46. Lynch JP 3rd, White ES. Pulmonary sarcoidosis. Eur Respir Mon 2005; 32:105-129.
47. Judson M.A. The treatment of pulmonary sarcoidosis. Respir Med 2012; 106:1351-1361.
48. Edey AJ, Hansell DM. Radiology of the lungs and pleura. In: Mitchell D, Wells A, Spiro S, Moller D, editors. Sarcoidosis. London: Hodder Arnold; 2012. pp. 73-93.
49. Mostard RL, van Kroonenburgh MJ, Drent M. The role of the PET scan in the management of sarcoidosis. Curr Opin Pulm Med 2013; 19:538-544.
50. Mostard RL, Verschakelen JA, van Kroonenburgh MJ, et al. Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. Respir Med 2013; 107:439-447.
51. Bargagli E, Mazzi A, Rottoli P. Markers of inflammation in sarcoidosis: blood, urine, BAL, sputum, and exhaled gas. Clin Chest Med 2008; 29:445-458.
52. Bargagli E, Bennett D, Maggiorelli C, et al. Human chitotriosidase: a sensitive biomarker of sarcoidosis. J Clin Immunol 2013; 33:264-270.
53. Vorselaars AD, Verwoerd A, van Moorsel CH, et al. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. Eur Respir J 2014; 43:602-609.
54. Conron M, Young C, Beynon HL. Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology 2000; 39:707-713.
55. Rottoli P, Rottoli L, Gommelli S, et al. Abnormalities in calcium metabolism in sarcoidosis. Sarcoidosis 1991; 8:180-181.
56. Meyrier A, Valeyre D, Bouillon R, et al. Different mechanisms of hypercalciuria in sarcoidosis. Correlations with disease extension and activity. Ann N Y Acad Sci 1986; 465:575-586.
57. Hamada K, Nagai S, Tsutsumi T, Izumi T. Ionized calcium and 1, 25-dihydrox-yvitamin concentration in serum of patients with sarcoidosis. Eur Respir J 1998; 11:1015-1020.
58. Kavathia D, Buckley JD, Rao D, et al. Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med 2010; 104:564-570.
59. Cox CE, Donohue JF, Brown CD, et al. Health-related quality of life of persons with sarcoidosis. Chest 2004; 125:997-1004.
60. De Boer S, Wilsher ML. Validation of the Sarcoidosis Health Questionnaire in a non-US population. Respirology 2012; 17:519-524.
61. Patel AS, Siegert RJ, Creamer D, et al. The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax 2013; 68:57-65.
62. Daniel A. Culver Gene-environment interactions in sarcoidosis: challenge and opportunity. Clin Dermatol 2007; 25:267-275.
63. Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA. Sarcoidosis susceptibility and resistance HLA-DQB1alleles inAfrican Americans. Am J Respir Crit Care Med 2003; 167:1225-1231.
64. Kreider ME, Christie JD, Thompson B, et al. Relationship of environmental exposures to the clinical phenotype of sarcoidosis. Chest 2005; 128:207-215.
65. Spagnolo P, Grunewald J. Recent advances in the genetics of sarcoidosis. J Med Genet 2013; 50:290-297.
66. Baughman RP, Judson M.A. Relapses of sarcoidosis: what are they and can we predict who will get them? Eur Respir J 2014; 43:337-339.
67. Chen ES, Moller DR. Sarcoidosis-Scientific progress and clinical challenges. Nat Rev Rheumatol 2011; 7:457-467.
68. Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29:119-127.
69. Doubková M, Posṕisil Z, Skricková J, Doubek M. Prognostic markers of sarcoidosis: an analysis of patients from everyday pneumological practice. Clin Respir J 2014. [Epub ahead of print]
70. Hanley ME, King TE Jr, Schwarz MI, et al. The impact of smoking on mechanical properties of the lungs in idiopathic pulmonary fibrosis and sarcoidosis. Am Rev Respir Dis 1991; 144:1102-1106.
71. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170:1324-1330.
72. Mooney JJ, Elicker BM, Urbania TH, et al. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest 2013; 144:586-592.
73. Teirstein AT, Morgenthau AS. 'End-stage' pulmonary fibrosis in sarcoidosis. Mt Sinai J Med 2009; 76:30-36.
74. Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc 2013; 10:362-370.
75. Patel DC, Budev M, Culver DA. Advanced ('end-stage') pulmonary sarcoidosis. In: Judson MA, editor. Pulmonary sarcoidosis: a guide for the practicing clinician. New York: Springer Science + Business Media; 2014. pp. 79-110.